Physician

Aarti Lothe Shevade, M.D.,

According to 2025 Medicare claims, Aarti Shevade, M.D., (NPI: 1548420888) practices hematology/oncology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Delaware, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 19096-3450.

Shevade's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 373 traditional Medicare patients, billed 122,812 HCPCS/CPT codes, and received $2,126,260 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,025 prescription claims across 204 beneficiaries totaling $1,973,202 in drug costs, led by Calquence (Acalabrutinib Maleate). 2023 DME data shows 96 claims. Open Payments data shows 136 records totaling $13,191. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $424,427 to $2,126,260. Similarly, Part D prescription costs have risen steadily, from $270,585 to $1,973,202. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,991 and ending at $4,538.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	285	59,846	$424,427
2016	366	96,920	$887,299
2017	356	188,178	$876,829
2018	365	164,581	$1,365,341
2019	399	146,825	$1,220,157
2020	358	142,078	$1,422,254
2021	373	141,258	$1,720,403
2022	411	155,602	$1,368,054
2023	384	144,565	$1,431,068
2024	373	122,812	$2,126,260

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	49	223	$270,585
2016	99	530	$557,106
2017	103	634	$1,042,240
2018	121	766	$1,548,577
2019	162	907	$1,813,970
2020	178	1,063	$1,855,476
2021	204	1,092	$1,795,594
2022	219	1,178	$1,867,968
2023	205	1,092	$1,630,377
2024	204	1,025	$1,973,202

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	36	$1,007
2019	N/R	286	$32,023
2020	N/R	68	$7,036
2021	N/R	N/R	N/R
2022	N/R	70	$1,673
2023	N/R	96	$4,887
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	59	59	$182
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	53	55	$149
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	166	383	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	132	157	$72
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	159	213	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	30	900	$434,075
Lenalidomide	Lenalidomide	18	427	$236,389
Ibrance	Palbociclib	12	336	$187,573
Promacta	Eltrombopag Olamine	14	420	$186,478
Venclexta	Venetoclax	20	568	$122,648

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	135	$3,191	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$10,000	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aarti Lothe Shevade, M.D., ?

Tedicare shows public-source Medicare data for Aarti Lothe Shevade, M.D., (NPI 1548420888), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aarti Lothe Shevade, M.D., have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aarti Lothe Shevade, M.D., ?

Aarti Lothe Shevade, M.D., is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Aarti Lothe Shevade, M.D., have Open Payments data?

Aarti Lothe Shevade, M.D., has 136 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.